Merck news - the latest biotech news from Labiotech.eu

$5.5M funding for Oncopole to tackle cancer

Jim Cornall — Tue, 06 Jun 2023 09:49:05 +0000

Oncopole, Fonds de recherche du Québec – Santé (FRQS) cancer division in Canada, has received major investments that boost its public-private partnership model dedicated to the fight against cancer. Oncopole will continue to pursue its mission thanks to a $3 million reinvestment from founding partner Merck Canada. Oncopole, FRQS cancer division, is the result of […]

The post $5.5M funding for Oncopole to tackle cancer appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Separation and analysis of empty and filled capsids during viral vector production

External Contributor — Tue, 09 May 2023 08:00:21 +0000

The post Separation and analysis of empty and filled capsids during viral vector production appeared first on Labiotech.eu.

Beyond Biotech podcast 42

Jim Cornall — Fri, 21 Apr 2023 11:01:48 +0000

This week, we’re talking about the upcoming Lund Spring Symposium with Claes Wahlestedt, Leonard M. Miller professor and director of the Center for Therapeutic Innovation (CTI) and associate dean for therapeutic innovation at the University of Miami Miller School of Medicine; about Meet2Win with Lucia Robert, CEO of MATWIN which stages the event; and then […]

The post Beyond Biotech podcast 42 appeared first on Labiotech.eu.

Infographic: Why choosing a client-centric CTDMO is critical when outsourcing biomanufacturing projects

Maya Chergova — Tue, 28 Mar 2023 08:00:29 +0000

In 2021, 28% of FDA approvals were granted to biologic drugs, showcasing the increasing demand for the biopharma industry to develop, manufacture and market biologic-based therapies. Biologic drugs include monoclonal antibodies and large molecules produced in mammalian cells, bringing the already complex process of drug development to a new level. Although the biomanufacturing of many […]

The post Infographic: Why choosing a client-centric CTDMO is critical when outsourcing biomanufacturing projects appeared first on Labiotech.eu.

The future of cancer treatment: Exploiting cancer’s key vulnerabilities

External Contributor — Wed, 01 Feb 2023 10:02:48 +0000

By Victoria Zazulina, M.D., head of development unit, oncology, for the healthcare business of Merck Since 2000, February 4 has been recognized as World Cancer Day and marked by efforts across the globe to raise awareness of the disease’s devastating impact and encourage efforts to improve prevention, detection and treatment. Over the past two decades, […]

The post The future of cancer treatment: Exploiting cancer’s key vulnerabilities appeared first on Labiotech.eu.

Mersana Therapeutics and Merck to develop novel ADCs

Jim Cornall — Fri, 23 Dec 2022 09:26:55 +0000

Mersana Therapeutics, Inc. has announced a research collaboration and commercial license agreement with a subsidiary of Merck KGaA, Darmstadt, Germany to discover novel Immunosynthen antibody drug conjugates (ADCs) directed against up to two targets. Immunosynthen, Mersana Therapeutics’ proprietary STING-agonist ADC platform, is designed to generate systemically administered ADCs that locally activate STING signaling in both […]

The post Mersana Therapeutics and Merck to develop novel ADCs appeared first on Labiotech.eu.

Merck and Kelun-Biotech collaborating on seven ADC cancer candidates

Jim Cornall — Fri, 23 Dec 2022 09:18:36 +0000

Merck (MSD outside of the U.S. and Canada), and Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd), have entered into an exclusive license and collaboration agreement to develop seven investigational preclinical antibody-drug conjugates (ADC) for the treatment of cancer. “Advances in ADC technologies are yielding a new generation of candidates designed to more […]

The post Merck and Kelun-Biotech collaborating on seven ADC cancer candidates appeared first on Labiotech.eu.

Infographic: your gene therapy manufacturing success recipe

Sudha Sundaram — Mon, 14 Nov 2022 11:49:16 +0000

By 2026, pharma industry insiders anticipate cell and gene therapy sales to significantly increase, with a real potential for these therapies to overtake conventional drugs in the biomedical space. With more than 600 active global trials today, industry insiders predict that the market value for gene therapies alone will exceed a staggering $10B (€8.5B) by […]

The post Infographic: your gene therapy manufacturing success recipe appeared first on Labiotech.eu.

Merck contributing to Jacobio Pharma colorectal cancer clinical trial

Jim Cornall — Thu, 13 Oct 2022 09:44:36 +0000

Jacobio announced it has entered into a clinical trial collaboration agreement with Merck on a clinical study of combination therapy between Jacobio’s KRAS G12C inhibitor JAB-21822 and Merck’s epidermal growth factor receptor (EGFR) inhibitor Erbitux (cetuximab). This clinical study aims to evaluate the efficacy of JAB-21822 in combination with cetuximab in patients with KRAS G12C-mutated […]

The post Merck contributing to Jacobio Pharma colorectal cancer clinical trial appeared first on Labiotech.eu.

TILT and MSD working on immunotherapy trial for non-small cell lung cancer

Jim Cornall — Mon, 26 Sep 2022 17:42:27 +0000

TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, has signed a second clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA, for a new clinical trial evaluating TILT-123, its oncolytic adenovirus armed with two human cytokines, in combination with KEYTRUDA (pembrolizumab), MSD’s anti-PD-1 therapy. The […]

The post TILT and MSD working on immunotherapy trial for non-small cell lung cancer appeared first on Labiotech.eu.

Astellas, Seagen and Merck give details on urothelial cancer treatment

Jim Cornall — Mon, 12 Sep 2022 17:58:27 +0000

Astellas Pharma Inc., Seagen Inc. and Merck (known as MSD outside of the U.S. and Canada), have announced results from the phase 1b/2 EV-103 clinical trial (KEYNOTE-869) Cohort K investigating PADCEV (enfortumab vedotin-ejfv) in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) and PADCEV alone as first-line treatment in patients with unresectable locally advanced or metastatic […]

The post Astellas, Seagen and Merck give details on urothelial cancer treatment appeared first on Labiotech.eu.

Investment of €130M made by Merck’s MilliporeSigma for life-saving therapies

Liza Laws — Thu, 08 Sep 2022 21:20:18 +0000

An investment of €130 million ($130 million) has been invested in Molsheim, France to strengthen manufacturing capabilities for single-use assemblies – a key technology for the production of Covid-19 vaccines and other life-saving therapies. The investment was made by MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA. It is the largest ever […]

The post Investment of €130M made by Merck’s MilliporeSigma for life-saving therapies appeared first on Labiotech.eu.

CRISPR/CAS9 strategic alliance between Sigma-Aldrich and genOway expanded

Liza Laws — Thu, 08 Sep 2022 16:04:51 +0000

Sigma-Aldrich Co LLC, along with genOway, a preclinical research model space company, announced today (September 8) they have a new structure to their 2018 strategic alliance in the CRISPR/Cas9 field. In 2018, science and technology company Merck, of which Sigma-Aldrich is a subsidiary, announced a strategic alliance in the CRISPR/Cas9 rodent model market with France-based […]

The post CRISPR/CAS9 strategic alliance between Sigma-Aldrich and genOway expanded appeared first on Labiotech.eu.

Merck puts up to $37B into Orna Therapeutics circular RNA collaboration

Jim Cornall — Tue, 16 Aug 2022 16:12:55 +0000

Merck, also known as MSD outside the U.S. and Canada, and Orna Therapeutics, a biotech company working on a new investigational class of engineered circular RNA (oRNA) therapies, are to collaborate on discovering, developing, and commercializing multiple programs, including vaccines and therapeutics, in the areas of infectious diseases and oncology. Under the terms of the […]

The post Merck puts up to $37B into Orna Therapeutics circular RNA collaboration appeared first on Labiotech.eu.

Immutep reports positive data from cancer study

Jim Cornall — Mon, 01 Aug 2022 14:21:08 +0000

Immutep Limited, an Australian biotech company developing LAG-3-related immunotherapy treatments for cancer and autoimmune disease, has announced new interim data from second-line NSCLC (non-small cell lung cancer) patients (Part B) in its phase 2 TACTI-002 trial. The data was presented at the IASLC 2022 World Conference of Lung Cancer (WCLC 2022) in Vienna, Austria, and […]

The post Immutep reports positive data from cancer study appeared first on Labiotech.eu.

BioMed X Institute and Merck start new oncology research project

Jim Cornall — Mon, 01 Aug 2022 10:01:05 +0000

BioMed X, a German independent research institute, has started a new research project ‘Extrachromosomal DNA in Cancer’ (EDC) in collaboration with the Healthcare Business of Merck KGaA, Darmstadt, Germany. The main objective of this research group is to develop an atlas of extrachromosomal DNA (ecDNA) in human cancer tissues and trace back the mechanisms of […]

The post BioMed X Institute and Merck start new oncology research project appeared first on Labiotech.eu.

Kelun-Biotech announces joint license agreement with MSD for drug targeting solid tumors

Liza Laws — Thu, 28 Jul 2022 10:25:38 +0000

Kelun-Biotech and MSD (Merck & Co.) have announced they are entering in a joint license agreement to develop a drug to treat solid tumors. The announcement was made yesterday (July 27) for the partnership to create the investigational antibody drug conjugate (ADC). Under the terms of the agreement, Kelun-Biotech, a clinical-stage biotech company focused on […]

The post Kelun-Biotech announces joint license agreement with MSD for drug targeting solid tumors appeared first on Labiotech.eu.

Five companies personalizing treatments with 3D printed drugs

Omnia Ibrahim — Thu, 28 Jul 2022 08:00:21 +0000

There has been a noticeable shift in recent years towards the personalization of medicine, with the pharmaceutical industry showing interest in pills that are tailored to a patient’s needs. Here are five companies that are leveraging 3D printing to produce customizable drugs. Conventional drug production relies on large-scale batch manufacturing, which is very efficient at […]

The post Five companies personalizing treatments with 3D printed drugs appeared first on Labiotech.eu.

You need to reach market readiness? What now?

Ute Boronowsky — Thu, 21 Jul 2022 08:00:50 +0000

Advancing a drug to market readiness is a major milestone. After successfully completing clinical studies, manufacturing and analytical processes must be adapted and optimized for commercial scale. Partnering with an experienced CDMO can help develop a strategy that balances speed, risk, and flexibility. But how do you find the best partner? Here’s a checklist. Identifying […]

The post You need to reach market readiness? What now? appeared first on Labiotech.eu.

Global call for scientists and inventors to form new startup

Liza Laws — Wed, 29 Jun 2022 20:34:07 +0000

A fourth start-up but the first of its kind sees some high-profile companies join forces in a hunt for new global research talent. AION Labs, an Israel-based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS) are focusing their start-up on the ‘prediction of clinical trial outcome in biomarker-stratified cancer patient […]

The post Global call for scientists and inventors to form new startup appeared first on Labiotech.eu.